News

Vistin Pharma ASA: Invitation to Q2 2022 conference call

Oslo, Norway, 11 August 2022 Vistin Pharma ASA will release its second quarter and YTD 2022 results on Friday 19th of…

2 years ago

Werewolf Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Highlights

- FDA granted IND clearance for lead candidate WTX-124 for evaluation as a treatment for advanced solid tumors - -…

2 years ago

ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology Programs

In line with corporate strategy update in April, ProQR to focus exclusively on the development of the Axiomer® RNA editing technology…

2 years ago

Aravive Reports Second Quarter 2022 Financial Results and Provides Corporate Updates

Hosted Key Opinion Leader (KOL) Symposium; KOLs Presented Positive Updated Batiraxcept Phase 1b Clear Cell Renal Cell Carcinoma (ccRCC) and…

2 years ago

argenx Announces European Commission Approval of VYVGART™ (efgartigimod alfa-fcab) for the Treatment of Generalized Myasthenia Gravis

VYVGART is the first neonatal Fc receptor (FcRn) blocker approved in Europe for the treatment of adults living with generalized…

2 years ago

Passage Bio Doses First Patient in Global Clinical Trial of PBFT02 Gene Therapy for Frontotemporal Dementia with Granulin Mutations

PHILADELPHIA, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing…

2 years ago

Teladoc Health Makes A1C Testing Easier for Members with Diabetes

At-Home Testing Improves Diabetes Care & Control for Individuals, Providers & Payers Alike PURCHASE, NY, Aug. 10, 2022 (GLOBE NEWSWIRE)…

2 years ago

Optimi Health Unveils Canada’s First Natural Therapeutic Psilocybin Product For Approved Patients

Blue Serenity (English) Optimi Health's, Blue Serenity psilocybin. Blue Serenity (English) Optimi Health's, Blue Serenity psilocybin. Blue Serenity Psilocybin Packaging…

2 years ago

Biora Therapeutics Announces Successful Completion of Device Performance Study in Ulcerative Colitis Patients for its Targeted Therapeutics Platform

All Devices Successfully Detected Colon Entry in Patients with Active Ulcerative ColitisSAN DIEGO, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Biora…

2 years ago

Arcutis Launches ZORYVE™ (Roflumilast) Cream 0.3% in the United States for Treatment of Plaque Psoriasis in Individuals Age 12 and Older

Next-generation topical PDE4 inhibitor for adults and adolescents with plaque psoriasis now available in pharmacies nationwideEffective, safe, and very well-tolerated…

2 years ago